Aktis Oncology Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, that develops targeted radiopharmaceuticals for the treatment of solid tumors. The company utilizes a proprietary miniprotein radioconjugate platform designed to deliver alpha-emitting radioisotopes directly to cancer cells while limiting exposure to healthy tissue. Its lead product candidate, AKY-1189, is in Phase 1b clinical trials for the treatment of Nectin-4 expressing solid tumors, including urothelial, breast, and colorectal cancers. A second candidate, AKY-2519, targets B7-H3-expressing tumors such as prostate and lung cancers. In addition to its wholly owned pipeline, Aktis maintains a strategic discovery collaboration with Eli Lilly to develop novel radioconjugates for other cancer targets.
